(Q34626130)

3 August 2017

title

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers (English)

1 reference

3 August 2017

1 reference

Peter Stopfer

1

1 reference

3 August 2017

Karin Rathgen

2

1 reference

3 August 2017

Daniel Bischoff

3

1 reference

3 August 2017

Silke Lüdtke

4

1 reference

3 August 2017

Kristell Marzin

5

1 reference

3 August 2017

Rolf Kaiser

6

1 reference

3 August 2017

Klaus Wagner

7

1 reference

3 August 2017

Thomas Ebner

8

1 reference

3 August 2017

language of work or name

English

0 references

publication date

4 January 2011

1 reference

3 August 2017

1 reference

3 August 2017

volume

41

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

297-311

1 reference

Predictability of the covalent binding of acidic drugs in man.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

Therapeutic options to target angiogenesis in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

The Orbitrap: a new mass spectrometer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

Measurement of Internal Acyl Migration Reaction Kinetics Using Directly Coupled HPLC-NMR: Application for the Positional Isomers of Synthetic (2-Fluorobenzoyl)-d-glucopyranuronic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.545452

10.3109/00498254.2010.545452

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference